Home » Topics » BioWorld Science

BioWorld Science
RSS

Agios initiates phase III ACTIVATE study of AG-348 in pyruvate kinase deficiency

June 19, 2018

Catalyst offers update from Cohort 6 in phase I/II trial of CB-2679d for hemophilia B

June 19, 2018

FDA grants fast track designation to mirvetuximab soravtansine in platinum-resistant ovarian cancer

June 19, 2018

Forge Therapeutics LpxC inhibitor shows activity in vitro, in vivo and in combination

June 19, 2018

Phase II results for talimogene laherparepvec plus pembrolizumab in patients with sarcoma

June 19, 2018

Safety run-in results presented from phase III ANDROMEDA study on daratumumab

June 19, 2018

Amgen initiates phase I trial of AMG-119 in small cell lung cancer

June 19, 2018

FDA issues complete response letter for Duobrii lotion

June 19, 2018

Brain sleepiness signature, links to memory identified

June 19, 2018

Phase Ib/IIa data for a small-molecule BET inhibitor PLX-51107

June 18, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...